StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Horizon Pharma (HZNP) PT Raised to $21 at Jefferies; Reiterates Buy
November 7, 2017 8:34 AM
Jefferies raised its price target on Horizon Pharma (NASDAQ: HZNP) to $21.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
November 6, 2017 12:00 PM
Pre-Open Movers 11/06: (TXMD) (VBLT) (CAVM) Higher; (S) (TMUS) (VZ) Lower (more...)
November 6, 2017 9:24 AM
Horizon Pharma (HZNP) Tops Q3 EPS by 4c, Beats on Revenues; Boosts FY17 Revenue & EBITDA Outlook
November 6, 2017 7:11 AM
Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
November 6, 2017 7:01 AM
Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
November 4, 2017 11:00 AM
National Health Partners (HPR) Announces Poster Presentation on KRYSTEXXA at ASN
November 3, 2017 11:02 AM
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
November 3, 2017 11:00 AM
